Abstract
Background The present study aimed to investigate the association between estradiol, acylated, des-acylated, total ghrelin levels along with pathological parameters and epithelial ovarian cancer (EOC) odds in postmenopausal women.
Methods A case-control study was carried out on 45 EOC patients and 33 age-matched postmenopausal women as the control group. Plasma levels of estradiol, acylated, des-acylated, and total ghrelin were measured by ELISA method.
Results Estradiol’s plasma levels were significantly higher in EOC patients compared to control women (P < 0.001). Although acylated, des-acylated, and total ghrelin levels were not associated with EOC in logistic regression models, estradiol levels were significantly related to the increase in EOC odds (OR: 1.083, 95% CI: 1.037-1.13, P < 0.001). However, estradiol levels in the two first quartiles (Q1, Q2) were associated with decreased odds of EOC (OR: 0.011, 95% CI: 0.001-0.118, P < 0.001, and OR: 0.030, 95% CI: 0.003-0.284, P = 0.002, respectively). For those patients in the third quartile of plasma des-acylated and total ghrelin compared to those in the highest (Q4), the multivariate odds ratios of EOC were respectively 0.192 and 0.25.
Conclusions In conclusion, higher concentrations of des-acylated and total ghrelin might be associated with the decreased EOC odds. Furthermore, the findings suggest that high levels of estradiol might be a potential odds factor in EOC, however, lower estradiol levels may have a protective effect on EOC development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received a grant from Kerman University of Medical Sciences, Kerman, Iran (Grant No. 940641).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset of the current study are available from the corresponding author on reasonable request.
